Cyted Wins £1 Million for Oesophageal Cancer Project

A £1 million fund has been given to a gastrointestinal wellbeing company, Cyted, to conduct its first personalised medicine research program targeting eosinophilic esophagitis. 

Innovate UK has provided funding to the diagnostics company to progress their non-invasive diagnostic tool called EndoSign. This test has been used to detect individuals susceptible to oesophageal cancer. 

Cyted has set out goals for the tool to provide medical professionals with information about an individual’s likelihood of responding to a specific treatment and determine the best plan of action.  

The leading executive of Cyted, Marcel Gehrung, commented, “This grant allows us to build on our existing diagnostic technology to help many more people with undiagnosed or ongoing oesophageal conditions.” 

Gehrung went on to add, “Our EndoSign platform will make a real difference to patients by decreasing the need for endoscopy and improving treatment decisions.” 

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.